In a mouse model of head and neck squamous cell carcinoma (HNSCC), combining anti-CTLA4 immunotherapy with the inhibition of Src family kinases (SFKs) showed a synergistic reduction in tumor growth. This evidence concerns the gene CTLA4 and neoplasm.